Medical Affairs Important Safety Information Prescribing Information For Patients Request Info

References

  1. Data on file. Available from CSL Behring as DOF PVG-006.
  2. Immune Deficiency Foundation (IDF). About primary immunodeficiencies. https://primaryimmune.org/about-primary-immunodeficiencies. Accessed August 3, 2022.
  3. Immune Deficiency Foundation (IDF). Specific diseases. https://primaryimmune.org/about-primary-immunodeficiencies/specific-disease-types. Accessed August 3, 2022.
  4. Immune Deficiency Foundation (IDF). Immunoglobulin (Ig) Replacement Therapy. https://primaryimmune.org/treatment-information/immunoglobulin-therapy. Accessed August 3, 2022.
  5. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11(6):532-538.
  6. Siegel J. IVIg medication safety: a stepwise guide to production selection and use. Pharm Pract News. Dec 2010.
  7. Siegel J. Immune globulins: therapeutic, pharmaceutical, cost, and administration considerations. Pharm Pract News. Jan 2010.
  8. GBS/CIDP Foundation International. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 101. https://www.gbs-cidp.org/cidp/. Accessed June 20, 2022.
  9. US Dept of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Chronic inflammatory demyelinating polyneuropathy (CIDP). https://www.ninds.nih.gov/Disorders/All-Disorders/Chronic-Inflammatory-Demyelinating-Polyneuropathy-CIDP-Information-Page. Accessed June 20, 2022.
  10. US Dept of Health and Human Services. National Institute of Health. National Heart, Lung and Blood Institute. Immune Thrombocytopenia (ITP). https://www.nhlbi.nih.gov/health/immune-thrombocytopenia. Accessed June 20, 2022.
  11. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances. 2019;3(23):3829-3866.
  12. Neunert C, Lim K, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;17(6):4190-4207.
  13. Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-236.
  14. US Dept of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. How is (ITP) treated? https://www.nhlbi.nih.gov/health/immune-thrombocytopenia#How-is-ITP-treated?. Accessed June 20, 2022.
  15. National Institutes of Health: ClinicalTrials.gov. Safety and efficacy of intravenous immunoglobulin IgPro10 in patients with primary immunodeficiencies. https://clinicaltrials.gov/ct2/show /results/NCT00322556. Accessed June 20, 2022.
  16. Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29(1):137-144.
  17. Data on file. Available from CSL Behring as DOF PVG-003.
  18. Cramer M, Frei R, Sebald A, Maeder M. Stability over 36 months of new liquid 10% polyclonial immunoglobulin product (IgPro10. Privigen®) stabilized with L-proline. Vox Sang. 2009;96(3):219-225.
  19. Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biological. 2010;38(1):150-157.
  20. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734-745.
  21. Sun A, Teschner W, Yel L. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Rev Clin Immunol. 2013;9(6):577-587.
  22. Simon HU, Späth PJ. IVIG mechanisms of action. Allergy. 2003;58(7):543-552.
  23. Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous polyclonal immunoglobulin in autoimmune diseases: clinical indications and mechanisms of action. Drug Discov Today Ther Strateg Autoimmun. 2009;6(1):5-11.
  24. Jacob S, Rajabally Y. Current proposed mechanism of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7(4):337-342.
  25. Imbach P, Lazarus AH, Kühne T. Intravenous immunoglobulin induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang. 2009;98(3):385-394.
  26. Centers for Disease Control and Prevention. National Center for Health Statistics--ICD-10-CM. https://icd10cmtool.cdc.gov. Accessed June 20, 2022.
  27. CPT Code 96365. Codify by AAPC. https://www.aapc.com/codes/cpt-codes/96365. Accessed June 20, 2022.
  28. CPT code 96366. Codify by AAPC. https://www.aapc.com/codes/cpt-codes/96366. Accessed June 20, 2022.
  29. HCPCS Code S9338. Codify by AAPC. https://www.aapc.com/codes/hcpcs-codes/S9338. Accessed June 20, 2022.
  30. HCPCS Code J1459. Codify by AAPC. https://www.aapc.com/codes/hcpcs-codes/J1459. Accessed June 20, 2022.
  31. Kobrinsky L. Prevalencer and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014 November;34(8):954-961. doi:10.1007/s10875-014-0102-8.
You are now leaving the current website.

Do you want to continue?